$10.54
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Is Kura Oncology (KURA) Undervalued On New FIT 001 Trial Data?
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story?
Overview
52-week range
$5.45
$12
72% of range
Avg surprise (last 3)
-207.9%
Avg reaction (last 2)
+0.4%
50% positive
Latest IV / EM
86%
EM ±19.7% · $11 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.83 | $-0.88 | +5.7% | -25.8% | +1.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.85 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.75 | $0.15 | -600.0% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-0.66 | $-0.51 | -29.4% | — | -1.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.63 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.59 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.59 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.50 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.53 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.89 | -$0.75 | -18.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18M | — | $21M | $15M | $14M | — | — | — |
| Cost of revenue | $262,000 | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-79M | — | $-80M | $-73M | $-65M | — | $-60M | $-56M |
| Net income | $-73M | — | $-74M | $-66M | $-57M | — | $-54M | $-51M |
| EPS (diluted) | $-0.83 | — | $-0.85 | $-0.75 | $-0.66 | — | $-0.63 | $-0.59 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $39M | $149M | $95M | $82M | $51M | $224M | $49M | $45M |
| Inventory | $843,000 | $413,000 | — | — | — | — | — | — |
| Total current assets | $624M | $709M | $621M | $660M | $724M | $745M | $463M | $500M |
| Total assets | $653M | $738M | $649M | $682M | $744M | $760M | $479M | $515M |
| Long-term debt | $10M | $10M | $5M | $7M | $8M | $7M | $8M | $9M |
| Total liabilities | $545M | $564M | $407M | $377M | $379M | $347M | $55M | $49M |
| Total equity | $108M | $174M | $243M | $305M | $364M | $414M | $424M | $466M |